Panic Disorder
📧 Sign up to get email alerts when something new happens for Panic Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders [Phase 2, Phase 3]
A completed Phase 2/Phase 3 clinical trial evaluating a quality-improvement approach to improve primary care for patients with anxiety disor…
-
FDA approval · 2014-01-10FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Zydus Pharmaceuticals USA Inc., authorizing its manufacturing and…
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic paroxetine hydrochloride product manufactured by NorthStar Rx LLC.
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Paroxetine hydrochloride hemihydrate from Mylan Pharmaceuticals, confirming the continued author…
-
CLINICAL_TRIALS research · 2013-12-30Clinical Trial Update: A Long-term Observational Study on the Efficacy of SSRIs or Combined Treatment(SSRIs+ CBT) in Panic Disorder Patients
Long-term observational study evaluating the efficacy of SSRIs alone or in combination with cognitive behavioral therapy for Panic Disorder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-12-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Venlafaxine Hydrochloride by Aurobindo Pharma Limited, updating the regulatory status of thi…
-
FDA approval · 2013-12-19FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine submitted by Padagis US LLC (NDA 204516).
-
CLINICAL_TRIALS trial_result · 2013-12-19Clinical Trial Update: The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder [Phase 4]
Phase 4 trial evaluating the efficacy and tolerability of duloxetine for panic disorder has completed, with results posted.
-
FDA approval · 2013-12-16FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride (generic sertraline), enabling a new generic versi…
-
CLINICAL_TRIALS research · 2013-11-20Clinical Trial Update: Evaluating the Effects of Stress in Pregnancy
A completed clinical trial investigates how stress during pregnancy may affect major depressive disorder, panic disorder, generalized anxiet…
-
FDA approval · 2013-09-26FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for ZOLOFT (sertraline hydrochloride) submitted by Roerig.
-
FDA approval · 2013-09-19FDA Approved: ALPRAZOLAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for Alprazolam from Aurobindo Pharma Limited (generic alprazolam). The approval pertains to a supp…
-
FDA approval · 2013-07-26FDA Approved: CLONAZEPAM — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for clonazepam filed by Par Health USA, LLC.
-
FDA approval · 2013-06-28FDA Approved: PAROXETINE — Original Application (Padagis US LLC)
FDA approved a paroxetine product from Padagis US LLC under an original application.
-
CLINICAL_TRIALS trial_result · 2013-06-27Clinical Trial Update: Psychodynamic Therapy for Treating Panic Disorder [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating psychodynamic therapy for panic disorder has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-25Clinical Trial Update: Therapy for Depression With Co-occurring Panic or Anxiety Symptoms [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating a therapy for depression with co-occurring panic or anxiety symptoms has completed.
-
FDA approval · 2013-05-31FDA Approved: CLONAZEPAM — Supplemental Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's supplemental application for clonazepam (generic) under ANDA075468, authorizing an additional clonazepam p…
-
CLINICAL_TRIALS research · 2013-05-16Clinical Trial Update: Physical Activity and Cognitive Behavioural Therapy in Panic Disorder [NA]
A completed clinical trial from Charité University in Berlin studied physical activity and cognitive behavioral therapy for panic disorder.
-
CLINICAL_TRIALS trial_result · 2013-05-08Clinical Trial Update: Study of Brain Circuitry in Anxiety Disorders
A completed McLean Hospital clinical trial investigated brain circuitry related to anxiety disorders, including posttraumatic stress disorde…
-
CLINICAL_TRIALS trial_result · 2013-02-21Clinical Trial Update: Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder [NA]
A randomized study comparing cognitive-behavioral therapy, imipramine, and their combination for panic disorder has completed.
-
FDA approval · 2013-02-01FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for ZOLOFT (sertraline hydrochloride) submitted by ROERIG.
-
FDA label_change · 2013-02-01FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA supplemental approval for sertraline hydrochloride from Mylan to update labeling.
-
FDA approval · 2013-01-29FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for sertraline hydrochloride from Rising Pharma Holdings, Inc., indicating approval of changes to th…
-
FDA approval · 2013-01-28FDA Approved: CLONAZEPAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for clonazepam from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2013-01-03FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
The FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.